Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Ablynx, Amgen, basket, biosimilar, bortezomib, Code, commenced, failed, glecaprevir, insignificant, intervening, MZL, naive, Nanobody, NDA, neuroendocrine, opted, Orange, pathway, protease, proteasome, provision, receipt, receptor, restitution, sensitive, Superior, unsuitable, VENCLEXTO, vobarilizumab, XR
Removed:
accrued, allocable, attributable, basic, British, calculation, comprised, Deferral, denominator, difficult, distributed, evolving, immaterial, inherently, meaningful, numerator, plan, Poor, pound, preparation, primary, qualify, refer, significantly, subjective, superseded, supported, uncertain, validated, variability, vary
Filing tables
Filing exhibits
Related press release
ABBV similar filings
Filing view
External links
Exhibit 12.1
RATIO OF EARNINGS TO FIXED CHARGES
The following table sets forth AbbVie’s historical ratios of earnings to fixed charges for the periods indicated. This information should be read in conjunction with the financial statements and accompanying notes included under Item 1, “Financial Statements and Supplementary Data” and Item 2, “Management's Discussion and Analysis of Financial Condition and Results of Operations.” This information should also be read in conjunction with AbbVie’s consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2015. For further information, see Exhibit 12.2 entitled “Computation of Ratio of Earnings to Fixed Charges”.
Nine months ended September 30, | Year ended December 31, | ||||||||||||
2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||||||||
Ratio of earnings to fixed charges | 7.7 | 8.0 | 6.0 | 16.6 | 41.3 | 132.0 |